SoFi CEO enters prepaid forward contract on 1.5 million shares
NEW YORK - Progyny, Inc. (NASDAQ:PGNY), a $1.78 billion women’s health benefits company currently trading below its InvestingPro Fair Value, announced Tuesday it is expanding its women’s health services to include pelvic floor therapy, addressing a condition that affects one in three women.
The company is adding both in-person and virtual care options by partnering with Origin and Hinge Health to provide specialized pelvic floor physical therapy services. Origin will offer nationwide in-network therapy both virtually and in-person, while Hinge Health will provide digital care supported by physical therapists specializing in pelvic health.
Pelvic floor disorders, which can cause urinary incontinence, pelvic pain, and sexual dysfunction, impact women from young adulthood through menopause. According to information cited in the announcement, urinary incontinence alone costs the healthcare industry $20 billion annually. This market opportunity aligns with Progyny’s strong financial performance, including 9.47% revenue growth in the last twelve months.
"This is another moment when Progyny is stepping up to help women identify and seek care for basic health needs that are going undiagnosed and untreated due to lack of education, lack of care access, and lack of the right benefits coverage," said Dr. Janet Choi, Progyny’s Chief Medical Officer.
The expanded services aim to provide earlier interventions for pelvic conditions and reduce fragmentation in care that can lead to delays in treatment. When left untreated, pelvic floor issues can interfere with quality of life, lead to reduced workplace performance, and result in avoidable health complications including potential infertility.
Progyny, which specializes in fertility and women’s health benefits, stated that the new offering will be part of its comprehensive women’s health and family building solutions.
The announcement was made in a company press release.
In other recent news, Progyny, Inc. reported strong financial results for the first quarter of 2025, significantly surpassing earnings expectations. The company achieved an adjusted earnings per share (EPS) of $0.48, well above the forecasted $0.18, and reported revenue of $324 million, marking a 16.5% increase from the previous year. Progyny also raised its full-year revenue guidance to a range of $1.185 billion to $1.235 billion, indicating growth between 1.5% and 5.8%. Additionally, the company has expanded its Medical Advisory Board with the inclusion of two prominent physicians, Dr. Gloria Richard-Davis and Dr. Whitney Booker, to enhance its expertise in women’s health.
In governance matters, Progyny held its 2025 Annual Meeting of Stockholders, where shareholders elected Class III directors, including Elizabeth Bierbower, and ratified Ernst & Young LLP as the independent registered public accounting firm. However, the proposal on executive compensation was not approved by the majority of shareholders. Furthermore, Progyny announced the appointment of Elizabeth Bierbower to its Board of Directors, highlighting her extensive leadership experience in the healthcare sector. These developments reflect Progyny’s ongoing efforts to strengthen its leadership and advisory teams while maintaining strong financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.